Understanding Whistleblower Protocols for Companies: A 2014 Perspective Live Webcast
20 August 2014
This is a must-attend event for anyone interested in understanding the significant issues relating to company whistleblower protocols.
Topics to be discussed include:
- The Age of the Whistleblower: The torrent of new legislation and regulations providing expansive protections for corporate whistleblowers continues unabated
- The growing number of federal and state laws which provide whistleblower protections, and make it easier for employees to reap financial rewards, has resulted in a significant increase in both government investigations and lawsuits by employees
- An update on key whistleblower laws and important legal trends, and a discussion of best practices for developing effective compliance and reporting programs to reduce the risk of whistleblower reports to regulators, as well as retaliation litigation
Course Fee: Registration is free to the first 30 registrants, courtesy of Foley. Once the first 30 registration spots are filled, Foley has arranged for others to register for the deeply discounted rate of $25.
Note: If CLE or CPE is needed, a minimal/partial processing fee is $49 for the registrant.
For additional information and to register for this event, please visit the Knowledge Group’s website.
People
Related Insights
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Article
FTC Finalizes Rule Against Employee Noncompetes
On April 23, 2024, the Federal Trade Commission voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.